The company finalizes a deal to establish its first manufacturing facility in Africa, which will have the capacity to produce 500 million vaccine doses per year.
Charles River and La Jolla Institute for Immunology (LJI) are collaborating on a new project to uncover how different cells in the human immune system respond to SARS-CoV-2 in early, acute infection.
Preclinical proof of concept study concludes SAM vaccine candidate delivered through CNE can rapidly elicit protective immunity against ZIKV, with potential use for additional antigens.
Researchers have discovered a virus that is unable to replicate in humans and is ‘tolerant to genetic manipulation’ that could be used to protect humans from dangerous infectious diseases.
